Advertisement
Canada markets close in 4 hours 22 minutes
  • S&P/TSX

    22,176.97
    +69.89 (+0.32%)
     
  • S&P 500

    5,253.19
    +4.70 (+0.09%)
     
  • DOW

    39,772.94
    +12.86 (+0.03%)
     
  • CAD/USD

    0.7385
    +0.0013 (+0.17%)
     
  • CRUDE OIL

    82.62
    +1.27 (+1.56%)
     
  • Bitcoin CAD

    96,251.34
    +2,381.78 (+2.54%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,236.30
    +23.60 (+1.07%)
     
  • RUSSELL 2000

    2,127.97
    +13.62 (+0.64%)
     
  • 10-Yr Bond

    4.1910
    -0.0050 (-0.12%)
     
  • NASDAQ

    16,398.60
    -0.93 (-0.01%)
     
  • VOLATILITY

    12.99
    +0.21 (+1.64%)
     
  • FTSE

    7,969.78
    +37.80 (+0.48%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6834
    +0.0029 (+0.43%)
     

Stocks in play: BioVaxys Technology Corp.

Announced today that it has entered into a major sponsored research collaboration with The Ohio State University to further develop BioVaxys' haptenized viral antigen platform to create a broadly reactive pan-sarbecovirus vaccine. This is the second research collaboration in the SARS-CoV-2 field between BioVaxys, a clinical-stage immunotherapy company developing novel approaches to harness T cells to treat cancer and to detect and prevent emerging infectious diseases; and Ohio State, a leading global academic research institute in the fight against SARS-CoV-2. Ohio State's Wexner Medical Center serves as a site for SARS-CoV-2 multicenter clinical trials. BioVaxys Technology Corp. shares C.BIOV are trading up 0.02 cents at $0.26.

Read: